Scientific Program

Day 1

KEYNOTE SPEAKERS
  • CONVENTIONAL VS. WHOLISTIC THERAPY, WHICH IS THE BETTER OPTION IN THE MANAGEMENT OF KNEE OSTEOARTHRITIS ASSOCIATED WITH OBESITY?

    Indian Medical Association
    India
    Biography

    Dr. John Ebnezar is an internationally renowned orthopedic surgeon, passionate about creating, conceptualizing, implementing preventive new orthopedic health awareness modules with an aim to propagate low-cost orthopedic health care. He is specialized in trauma, spine, geriatric orthopedics and sports medicine. He holds Guinness World Records both for academics (2010) and social service (2015), an only orthopedic surgeon in the world to do so. He is a Ph.D. in yoga, involved in 6 original-yoga kinds of research, won Best Research Award from Vyasa Yoga University (2012) for his work on knee arthritis and role of yoga in fracture healing (2010). He has pioneered a new treatment method, WHolistic Orthopedics, by blending modern orthopedics with Indian Yoga, which is simple, cheap, effective alternative for patients for whom knee replacement is not an option and also for patients with modern lifestyle orthopedic problems and has redefined the way orthopedic ailments are treated across the globe. He has authored more than 200 books in Orthopedics, a World Record, and has more than 60 Scientific publications which have been cited more than 150 times.

    Abstract

    Osteoarthritis knee is the most common joint disorder affecting nearly 10% of the world population. There are several non-modifiable and modifiable risk factors for OA Knees with obesity being the greatest modifiable risk factor. How excess weight influences OA is not clear. Obesity has both a mechanical and inflammatory component in the development and worsening of knee arthritis. Traditionally osteoarthritis knees have been treated with non-pharmacological, pharmacological and surgical methods. When OA Knee is associated with obesity where the situation is far more complex, these treatment methods are not effective. There is a need for a paradigm shift from conventional to comprehensive treatment. A patient with OA and obesity knees suffer and not in isolation and the traditional treatment methods alone may not be enough. Yoga with its multidimensional approach of body, mind and soul implications could be an answer. Extensive research on the role of yoga as an add-on in the treatment of OA knees associated with obesity has shown excellent to good results. My research studies were picked up by American Association of Orthopedic Surgeons (AAOS) in formulating the 2013 Non-Arthroplasty treatment guidelines for OA Knees. A broad-based treatment called wholistic treatment keeping yoga as the central option in the treatment of OA Knees and Obesity seems to be the best option.

  • DIABETES MELLITUS AND LEPROSY: NEW EDUCATION PROTOCOL IN FOOT AT RISK AT THE SANTA MARCELINA HOSPITAL, AMAZON, BRAZIL

    The Santa Marcelina Hospital
    Brazil
    Biography

    Orlando L Cravalho has completed his Medical College from Amazon Federal Medical College, and he was specialist in Endocrinology from Gama Filho University. He is the Director of Santa Marcelina Hospital, Porto Velho. He is the Coordinator of The State Service of Endocrinology, Diabetic Foot Service Coordinator, Professor of Medical School São Lucas, Porto Velho, Rondônia , Amazon, Brazil.

    Abstract

    Objective: To apply an intensive and multidisciplinary education protocol to decrease, improve, delay or cancel the beginning of neuropathy and the manifestation of lesions in diabetic patients. Methodology: This is a cross-sectional descriptive study carried out at the Diabetes Mellitus Outpatient Clinic and ward of Santa Marcelina Hospital in Porto Velho. This research was based on cases of patients with Diabetes and Diabetics with Leprosy. The criteria used to include the patients were: being treated with insulin therapy, not to be amputated, being on high medication of the leprosy now of the evaluation and to present nutritional risk classification by the screening. The population was divided into two groups of fifteen patients: eight diabetic patients, four male and four females. Seven diabetics associated with leprosy were free males and three females. Results & Discussion: Group A, called the intensive care group, began diabetes education work with medical, nutritional and rehabilitation guidelines by a multidisciplinary team. Group B, called conventional care, received the same guidelines in outpatient care and the monitoring followed the quarterly protocol. Both groups were evaluated and reassessed for a period of 180 days in the outpatient clinic. Group A consisted of eight (100%) patients, four (50%) diabetics and four (50%) diabetics and leprosy patients. Conclusion: This research highlights, once again, the importance of integration among the specialties. Therefore, experimental models of multidisciplinary clinic outpatient of clinics should be encouraged in clinical practice to promote a more comprehensive care on different functional aspects. Intensive education in diabetes showed an improvement in the sensitivity, healing and nutritional status of the patients, leading to an improvement in quality of life and disability, reducing or delaying the inception of neurological complications. The intensive form of the protocol demonstrated a 100% improvement in patients in group A.

  • CONSTRUCTION AND CHARACTERIZATION OF YEAST DISPLAY OF VIRAL CAPSID PROTEIN: A PRELIMINARY IMPLICATION FOR PRODUCTION OF ORAL VACCINE AGAINST NERVOUS NECROSIS VIRUS

    Burapha University, Thailand
    Thailand
    Abstract

    Nervous necrosis virus (NNV) causes viral nervous necrosis that often reaches higher than 99% mortality rate in hatchery-reared larvae and juveniles. There are still no effective vaccines currently available for NNV. Yeast surface display of capsid proteins of red-grouper-nervous- necrosis virus (RG-NNV) was constructed aimed at developing an oral vaccine in fish. RG-NNV infection in fingerlings or juveniles that showed clinical signs of abnormal swimming patterns was proved by RT-PCR and DNA sequencing. The 2,100 bp of DNA fragment containing RNA2 capsid protein of RG-NNV fused to AG?1 of S cerevisiae in linearized pPIC9K vector was electroporated into P pastoris GS115. Yeast auxotroph isolates were preliminary selected by histidine-producing ability and geneticin resistance. The recombinant yeasts were cultured in buffered minimal glycerol-complex medium (BMGY) and induced with 0.5% methanol in buffered minimal methanol complex medium (BMMY). Only 50% of the expression of the fusion proteins was detected by Western blot. Immunofluorescence labeling confirmed the correct localization and the predicted tertiary structure proposed the exposed conformation of the fusion protein on the cell wall. Optimization of protein expression is required for fully surface protein expression before the evaluation of the possible use of the capsid protein displayed yeast as an oral vaccine against RG-NNV infection.

  • VACCINATION IN PATIENTS IN USE OF IMMUNOBIOLOGICAL DRUGS FOR IMMUNE MEDIATED DISORDERS

    Santhè Clinic
    Brazil
    Abstract

    Immune mediated inflammatory disease (IMID) is a concept used to describe a group of conditions that share common inflammatory pathways. Encompassing disorders as ankylosing spondylitis, multiple sclerosis, psoriasis, arthritis psoriatic, rheumatoid arthritis, hidradenitis suppurativa and inflammatory bowel diseases, the immune dysregulation may afflict any organ system and result in significant morbidity, reduced quality of life (QoL) and premature death. Although the aetiology of these conditions is unknown, advances in molecular research have revealed that an imbalance in inflammatory cytokines is central to their pathogenesis. The most convincing evidence linking the pathophysiology and treatment of autoimmune diseases has been demonstrated with the tumour necrosis factor?? (TNF?) inhibitors. The therapeutic aims for the drugs used for the treatment IMIDs are: to gain rapid control of inflammation, prevent tissue damage, improve QoL and, if possible, achieve long?term disease remission. This drug is named immunobiological drugs. Their use is related to immunosuppression, and the patient who will be submitted to this kind of treatment needs to be vaccinated. However, severe complications have followed vaccination with live, attenuated virus vaccines and live bacterial vaccines among immunocompromised patients. In general, these patients should not receive live vaccines. The aim of the present study is to standardize conduct of vaccination in patients using immunobiological drugs.

Vaccination and Immunisation | Childhood Obesity | Diabetes and Endocrinology
Chair
Co-Chair

Day 2

KEYNOTE SPEAKERS
  • PRE-CLINICAL & CLINICAL DEVELOPMENT OF BIOSIMILAR INSULINS/INSULIN ANALOGUES: THE CLINICAL IMPLICATIONS OF CRITERIA FOR SIMILARITY

    Wockhardt Ltd
    India
    Biography

    Agam Shah has rich professional experience of nearly 15 years in clinical development, medical affairs, and academics. He has been an avid Clinical Research Physician with numerous scientific publication and presentations to his name. He has comprehensive experience of clinical development of biosimilars, complex generics and vaccine products.

    Abstract

    Introduction: Akin to generic product development through pharmaceutical equivalence followed by bioequivalence compared to reference medicinal product to ascertain similar safety and efficacy, biosimilar insulin/analogue product (BIP) development includes physio-chemical-biological characterization followed by human PK-PD study and safety-efficacy-immunogenicity study compared to reference insulin product (RIP) to ascertain the same. Although, development of multiple biosimilar insulin products has been undertaken throughout the world, clarity about the clinical implications of the results of these studies is not much discussed. Objective: To assess the clinical implications of pre-clinical and clinical studies undertaken on BIP to establish its similarity to their RIP in terms of their results. Methods: Results of studies conducted by Wockhardt Ltd. for development of their BIP of insulin glargine as per in comparison to RIP were evaluated to assess their criteria for similarity in the context of clinical implications. Results: Results of the in vitro receptor binding assays, in vitro receptor auto-phosphorylation, in vitro metabolic assays and in vivo PD studies indicate that BIP is comparable to the RIP in the potential for glucose lowering effects. Whereas, results of the in vitro mutagenicity assays, sub-chronic toxicity study indicate that BIP is comparable to the RIP in potential for toxicities, pharmacokinetics and immunogenicity. Results of human PK-PD studies conducted in healthy volunteer and type 1 diabetics under euglycemic clamp settings proved that BIP is bioequivalent to the RIP in glucose lowering effect and insulin glargine exposure. Whereas, results of comparative safety-efficacy-immunogenicity studies in type 1 and type 2 diabetics confirmed that BIP is non-inferior to RIP in glycaemic control as well as comparable to it in hypoglycaemic events, other adverse events and immunogenicity. Conclusion: Pre-clinical and clinical development data on BIP offers comprehensive information of clinical PK-PD, safety, efficacy and immunogenicity in comparison to RIP to understand clinical implications of BIP’s use in practice.

  • AUTOLOGOUS CELL REPLACEMENT THERAPY FOR DIABETIC PATIENTS BY LIVER TRANSDIFFERENTIATION

    Sheba medical center
    Israel
    Abstract

    Trans differentiation is the direct reprogramming of adult cells into alternate cell types with different function. Liver to pancreas transdifferentiation (TD) induced by ectopic expression of pancreatic transcription factors (pTFs) was first described by our group both in vivo and in human liver cells in vitro. The keynote lecture will disclose our understanding of the mechanism of liver to pancreas TD and will describe this approach’s industrial implementation as an autologous cell replacement therapy for diabetic patients. Our data suggest that TD occurs in predisposed liver cells that display specific characteristics. Moreover, TD-propensity can be extended to most of the cells by epigenetic manipulations, hence, increasing the trans differentiation efficiency. Using primary cultures of liver derived from >20 human donors we have identified a sub-population of human liver cells that are persistently predisposed to undergo TD (5-15% of the cells). Upon ectopic pTFs expression, 70% of the predisposed liver cells produced and secreted the processed hormone in a glucose-regulated manner. Epigenetic analyses suggested that pancreatic genes’ chromatin is more transcrpition-permissive in TD-predisposed than in recalcitrant liver cells. TD-predisposed liver cells display a reduced level of DNA methylation which further decreases upon the induction of reprogramming. Using epigenetic modifiers, we could convert TD-resistant liver cells into TD-permissive cells. Moreover, in vitro culturing of the AIP cells in a 3D organoid manner, and their exposure to a suitable and relevant niche, increased the transdifferentiated liver cells maturation insulin production. In summary, pancreatic TD is restricted to a specific cell population within the adult liver tissue, which harbors obligatory signaling patterns and specifically permissive epigenome. The extension of TD-propensity to most of the cells in culture/tissue, is expected to dramatically increase this process efficiency bringing it closer to its therapeutic implementation, as an autologous cell replacement therapy for diabetic patients.

  • THE PRESENT AND FUTURE OF VACCINEAL PREVENTION OF ANIMAL BRUCELLOSIS

    Moscow State Academy of Veterinary Medicine and Biotechnology-MVA K. I. Skryabin, Russia
    Russia
    Biography

    Saida Marzanova has completed her Ph.D. at the age of 25 years from Moscow State Academy of Veterinary Medicine and Biotechnology-MVA K. I. Skryabin, Russia. She is the Associate Professor of Moscow State Academy of Veterinary Medicine and Biotechnology-MVA K. I. Skryabin, Russia. She has over 50 publications that have been cited over 25 times, and her publication H-index is 3 and has been serving as an editorial board member of reputed Journal “Veterinary Medicine

    Abstract

    The effectiveness of corrective measures for brucellosis is largely determined by the quality of epidemiological surveillance and the effectiveness of vaccine prevention. Used live vaccines do not fully protect against infection, at the same time they pose a potential risk of Brucella infection in animals with low immune resistance and post-vaccination complications and pose a danger to livestock breeders and the population consuming untreated products from vaccinated animals. Inactivated vaccines did not find practical application due to insufficient efficacy and high reactogenicity. Considering that vaccination is the basis for the prevention of Brucella infection, we conducted studies on the selection of strains, developed and experimentally tested a split conjugated biosafe vaccine based on immunogenically active subcellular and soluble peptides of three Brucella strains: B.melitensis and two strains of Brucella bovis biotype. To stimulate specific immunity, Brucella antigens were conjugated to an immunoprotector. The immunoprotector was obtained from a culture of B lymphocytes sensitized with Brucella antigens. Activity control was assessed by immunostimulating of the mechanisms of cellular and humoral immunity and immunogenic activity of the vaccine in guinea pigs. The immunogenic activity of the declared vaccine was studied on guinea pigs weighing 300-400 g, which were subcutaneously injected into the groin area with test specimens of vaccines at a dose of 0.5 cm3. After four weeks vaccinated guinea pigs were infected with a virulent culture of B. bovis 10 in an infectious dose (ID). At the same time, non-vaccinated (control) guinea pigs were infected. 30 days after infection, guinea pigs were killed and bacteriological seeding of lymph nodes and organs on Brucella agar and Brucella broth was performed. Seeding was sterile in 100% of vaccinated guinea pigs. In seeding from control unvaccinated guinea pigs in 100% of cases, a culture of Brucella of the infecting strain was isolated. As, a result, immunization of the split-conjugated brucellosis vaccine activates the cellular and humoral immune response, enhancing the induction of specific antibodies. Advantages of a split-conjugated vaccine: biosafety, protection of immunized animals from infection with brucella during experimental infection, reliably exceeds the specific efficiency of live anti-brucella vaccines from strains B. abortus 19 and B. melitensis Rev-1.

Gynecology and Obstetrics | Diabetes Case Study and Research | Vaccine Development and Production | Diet and Nutrition
Chair
  • Allied Academies Vaccines Congress 2018 Chair Speaker Davud A Devrishov photo
    Davud A Devrishov
    Moscow State Academy of Veterinary Medicine and Biotechnology-MVA K. I. Skryabin, Russia
    Russia
Co-Chair

Mail us at

Drop us an email for Program enquiry
vaccines@alliedscholars.com
Sponsors/Exhibiting/Advertising
vaccines@alliedscholars.net
Sponsors/Exhibiting/Advertising
vaccinecongress@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

Insurance

Registration fees do not include insurance of any kind.

Transportation

Please note that any (or) all transportation and parking is the responsibility of the registrant.

Press/Media

Press permission must be obtained from Allied Academies Conferences Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies Ltd is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact vaccines@alliedscholars.com to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrant's account.

This cancellation policy was last updated on April 04, 2018.

Cancellation, Postponement, and Transfer of Registration

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

Cancellation Policy

If Allied Academies Group cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Group event which must occur within one year from the date of cancellation.

Postponement

If Allied Academies Group postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Ltd event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to finance@alliedacademies.com. Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies Ltd if the person is unable to attend one of the conferences.

However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies Ltd will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies Ltd, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 90 days of the conference: Eligible for Full Refund less $100 Service Fee
  • Within 90-60 days of Conference: Eligible for 50% of payment Refund
  • Within 60 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies Ltd will advise the cancellation policy of your accommodation provider, prior to canceling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

 

Authorization Policy


Copyright © 2019-2020 Allied Academies, All Rights Reserved.